Pirtobrutinib Extends Progression-Free Survival to 14 Months in BTK-Inhibitor-Pretreated CLL Patients

The phase 3 CLL-321 trial enrolled patients whose disease had progressed after prior covalent BTK inhibitor therapy. Participants were randomly assigned to receive pirtobrutinib or the investigator's choice of bendamustine or idelalisib, reflecting real‑world treatment options. Most patients had also been exposed to BCL‑2 inhibitors and were heavily pretreated.

Updated analysis showed a median progression‑free survival of about 14 months for the pirtobrutinib arm, compared with 8.7 months for the control arm. The advantage persisted in subgroup analyses, including patients with and without prior venetoclax exposure.

Safety data indicated low cardiac toxicity and no new safety concerns emerged during the study, supporting a favorable tolerability profile for pirtobrutinib.

These results suggest that pirtobrutinib could become a preferred option for CLL patients who have exhausted covalent BTK inhibitors, offering a meaningful extension of disease control with manageable side effects.